ELIZABETH URBANEK ARTICLES
-
Merck Ends Nemtabrutinib Development, Closing Three Phase 3 BELLWAVE Trials11/20/2026
Merck has discontinued nemtabrutinib development and three Phase 3 trials, leaving clinical supply teams to coordinate IMP returns, comparator inventory, reconciliation and program-wide close-out.
-
Los Angeles And Long Beach Port Talks Stall Ahead Of Saturday Strike Deadline11/19/2026
Contract talks at the Los Angeles and Long Beach ports have stalled ahead of a Nov. 21 strike deadline, putting inbound clinical trial shipments, refrigerated containers and U.S. depot inventory at risk.
-
FDA Launches Program To Share Approval Reviews With Foreign Regulators, Expanding To Novel Drugs In 202711/18/2026
FDA's Global Reliance Disclosure Program could shorten foreign drug approvals, affecting continued-access supply, country-specific labeling, and IMP distribution timelines.
-
FDA Rejects Summit's Ivonescimab, Citing Lack Of Statistically Significant Overall Survival Benefit11/17/2026
FDA's rejection of ivonescimab raises questions about longer survival-driven trials, investigational drug inventory, comparator sourcing, and clinical supply forecasting.
-
Identity Security In Clinical Trial Supply: Who Has Access, And Why?11/13/2026
Explore how identity verification, role-based access, and audit trails help protect clinical trial supply systems from unauthorized changes, identity fraud, and access risks.
-
Shenzhen APEC Restrictions And Bangkok Cargo Backlog Squeeze Air Freight Lanes Into South China And Thailand11/13/2026
Shenzhen APEC cargo restrictions and a Bangkok warehouse backlog threaten air freight capacity and temperature-sensitive pharmaceutical shipments moving into Asia.
-
FDA Draft Guidance Spells Out Dose Escalation And Expansion Expectations For Early-Phase Solid Tumor Trials11/12/2026
FDA draft guidance outlines dose escalation and expansion expectations for early-phase solid tumor trials, with implications for IMP presentations and clinical supply planning.
-
Kalaris Expects TH103 Data In Second Half Of 2027 After Clinical Batch Misses Specification11/11/2026
Kalaris Therapeutics delays TH103 trial data after a manufacturing batch fails release testing, highlighting the supply risks of single-batch clinical programs.
-
Los Angeles And Long Beach Port Strike Deadline Moves To Nov. 20, Keeping Ocean Freight Risk In Play11/10/2026
Contract talks at Los Angeles and Long Beach ports extend to Nov. 20, leaving ocean shipments of clinical trial materials exposed to potential delays and disruption.
-
FDA Investigates Zolgensma Malignancy Risk, Puts Other AAV Gene Therapy Programs On Watch11/9/2026
FDA investigation of Zolgensma-related malignancy risk puts AAV gene therapy sponsors on alert for potential dosing delays, inventory impacts and clinical trial supply decisions.
-
Lessons From Ebola And Marburg: Building Clinical Trial Supply Chains Under Pressure11/9/2026
Lessons from Ebola and Marburg vaccine trials reveal how cold chain readiness, trained personnel, and contingency planning help maintain clinical supply under pressure.
-
U.S. Launches Key Starting Materials Survey, Putting Upstream Drug Supply Risk In Focus11/6/2026
Federal agencies will survey the U.S. key starting materials base, a review that reaches the upstream sources behind IMPs, APIs, and comparators.
-
India Proposes 10 New Drug Import Gateways, Including Inland Depots And Noida Airport11/5/2026
India proposes 10 new drug import gateways, potentially shortening IMP transport routes and changing customs clearance considerations for clinical trial supply teams.
-
Safi Biotherapeutics Secures $4.7 Million To Advance Manufactured Red Blood Cells Toward First Clinical Trial11/4/2026
Safi Biotherapeutics secures $4.7 million to advance manufactured red blood cells toward clinical trials, raising manufacturing, storage and distribution considerations.
-
FDA Finalizes Cell And Gene Therapy Potency Guidance, Putting Manufacturing And Supply Controls in Focus11/3/2026
FDA's final cell and gene therapy potency guidance highlights how manufacturing, storage, transportation and handling decisions can affect product quality and delivery.
-
Kerala Probes Remdesivir Procurement And Inventory Records Following Nipah Treatment Questions11/2/2026
Kerala investigates remdesivir procurement records, batch traceability and expiry controls after questions emerge about medication supplied to government hospitals.
-
Experic Secures Irish Authorization For Clinical Trial Supply Facility, Connecting U.S. And EU Operations10/29/2026
Experic's Irish facility gains authorization for IMP importation, QP release, packaging and distribution, expanding options for sponsors managing EU clinical supply.
-
FDA Draft Guidance Could Change How Sponsors Plan Individualized Gene-Editing Therapies10/28/2026
FDA draft guidance proposes a framework for managing individualized gene-editing variants under one application, with implications for manufacturing, labeling and clinical supply planning.
-
Radiopharmaceutical Manufacturing Capacity Could Become A Bottleneck For Clinical Trials10/27/2026
Radiopharmaceutical manufacturing capacity and isotope availability could constrain clinical trials as demand grows, making early production and delivery planning critical.
-
Clinical Trial Supply Challenges In Alzheimer's Trials10/27/2026
Alzheimer’s trials challenge clinical supply teams with volatile enrollment, global distribution, cold chain needs, real-time forecasting and patient-centered planning.
-
Perspective Therapeutics Advances Phase 3 Preparation As Manufacturing Capacity Scales10/26/2026
Perspective Therapeutics prepares for a Phase 3 radiopharmaceutical trial as manufacturing capacity expands, raising questions about isotope access and site readiness.
-
Kerala's Trial-Labeled SMA Medicine Raises Questions About Inventory Controls10/23/2026
Medicine labeled for clinical trials reached children receiving routine SMA treatment in Kerala, raising questions about inventory controls, labeling and supply authorization.
-
Syneos Health And Optum Target Clinical Trial Planning With New Partnership10/21/2026
Syneos Health and Optum are developing adaptive clinical trial planning capabilities that could help sponsors anticipate protocol changes and supply risks earlier.
-
AstraZeneca And Oracle Explore AI To Improve Clinical Trial Recruitment10/20/2026
AstraZeneca and Oracle are exploring AI for clinical trial recruitment, raising questions about how earlier enrollment insights could shape clinical supply forecasting and resupply plans.
-
Filament Health To Supply Psilocybin For Proposed Belgian Compassionate Use Program10/19/2026
Filament Health will supply psilocybin for a proposed Belgian compassionate use program, pending regulatory approval and required authorizations for cross-border supply.
-
Prelude Therapeutics And Lilly Agree To Supply Drugs For Combination Trial10/15/2026
Prelude Therapeutics and Lilly agree to supply two medicines for a Phase 1 breast cancer trial, highlighting coordination needs as the study advances to combination cohorts.
-
Lonza Expands DNA-To-IND Pathway For Complex Biologics10/14/2026
Lonza expands its accelerated DNA-to-IND pathway to complex biologics, targeting IND readiness in as little as six months and raising clinical supply planning considerations.
-
FedEx Europe Launches Digital Portal For Temperature-Controlled Pharmaceutical Shipments10/13/2026
FedEx launches a digital booking portal across 26 European markets for temperature-controlled pharmaceutical shipments, packaging orders, scheduling, and returns.
-
Andelyn Biosciences And PQP Group Establish EU And UK Supply Pathway For Cell And Gene Therapies10/9/2026
Andelyn Biosciences and PQP Group partner to coordinate import, QP certification, and distribution for cell and gene therapies entering European clinical supply markets.
-
What Your Tier 1 Supplier Map Might Be Missing10/8/2026
Your Tier 1 supplier map may not show the dependencies that can actually stop clinical supply. David Fairnie explains how to uncover hidden vulnerabilities.
-
FDA Transparency Roadmap Could Give Clinical Supply Teams More Visibility10/7/2026
FDA transparency efforts could give clinical supply teams more insight into regulatory and inspection risks that may affect manufacturing, inventory and distribution.
-
NIHR Centre Creates New IMP Transfer Process With Potential To Scale Across UK10/6/2026
NIHR establishes a governed IMP transfer process between clinical trial sites, creating a potential new approach to managing site-level inventory, demand and clinical supply.
-
Rare Disease Trials: Execution Risks No One Warns You About10/6/2026
Rare disease trials demand a different approach to site selection, forecasting, supply, and patient logistics because every patient counts. Explore what can go wrong.
-
AI In Clinical Supply: From Forecasting To Execution Decisions8/25/2026
AI could shift clinical supply from periodic forecasting to continuous decisions, linking live signals with execution while protecting quality and patient continuity now.
-
When IRT Configuration Decisions Disrupt Clinical Supply8/17/2026
IRT decisions can make or break clinical supply. Craig Mooney explains how configuration, enrollment, inventory, and human oversight shape trial execution.
-
When Clinical Supply Plans Meet Site Reality: Lessons From The Front Line8/11/2026
Clinical supply plans can look perfect on paper but fail at the site. A Moorfields surgeon explains how supply delays, packaging, and workflow gaps affect trials and patients.
-
Building Trust In Clinical Supply Digital Transformation7/30/2026
Digital transformation succeeds when clinical supply teams trust their data, systems, and decisions. Explore how governance and adoption unlock better outcomes.
-
South Africa In Clinical Trial Supply: An Underrecognized Capability7/23/2026
Many sponsors still plan for South Africa using outdated assumptions. Learn how current regulatory, logistics, and supply capabilities support reliable clinical trial execution.
-
Engaging Commercial Supply Chain Professionals Early In Clinical Supply Selection7/2/2026
Supplier decisions made during early clinical development can create hidden commercialization risks. Learn why involving commercial supply chain experts earlier changes outcomes.
-
AI In Clinical Trial Supply Chains6/22/2026
AI is moving into clinical trial supply decisions, but value depends on judgment, assumptions, and system integration, not speed or automation.
-
Clinical Trial Supply Failures Start Before First Patient In6/12/2026
Many trial supply disruptions are set in motion years before enrollment begins. Hedley Rees explains how early decisions shape risk, forecasting, inventory, and execution.
-
Clinical Trial Supply Impact Of ICSR Processing Delays6/11/2026
Safety reporting delays can ripple through RTSM, inventory allocation, and resupply planning, creating hidden risks that disrupt clinical trial supply execution.
-
How The Iran Conflict Threatens Global Clinical Supply Chains6/9/2026
Geopolitical disruption is exposing hidden weaknesses in clinical supply networks, forcing sponsors to rethink inventory, depots, comparators, and trial continuity.
-
Clinical Supply Chain Continuity And Resilience6/4/2026
Clinical supply disruptions can derail trials fast. Learn how sponsors build resilience through smarter forecasting, supplier strategy, and continuity planning.
-
Geopolitical Risk Is Reshaping Clinical Trial Supply Chains5/12/2026
Rising geopolitical risk and fuel volatility are breaking clinical supply assumptions, forcing new strategies to protect trial timelines, patient access, and product integrity.
-
Building Win-Win Partnerships In Clinical Trial Supply3/30/2026
Strong supplier partnerships are the backbone of reliable clinical trial supply, driving speed, flexibility, and better outcomes through trust, transparency, and shared goals.
-
Leading Clinical Trial Supply Teams: Insights And Best Practices3/25/2026
Strong clinical trial supply leadership drives trial success through trust, collaboration, and proactive planning across teams, timelines, and complex global supply challenges.